HRAS and cancer: We found that PI3K-AKT signaling pathway was significantly inhibited in NRAS, KRAS, and HRAS mutant-cancer cell lines upon treatment with BAY 11-7082 as observed by reduced p-AKT protein level (Fig. 4A, E, I).